Culture conversion at six months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis.

Auteurs: Seung KJ Khan P Franke MF Ahmed S Aiylchiev S Alam M Putri FA Bastard M Docteur W Gottlieb G Hewison C Islam S Khachatryan N Kotrikadze T Khan U Kumsa A Lecca L Tassew YM Melikyan N Naing YY Oyewusi L Rich M Wanjala S Yedilbayev A Huerga H Mitnick CD
Référence de l'article: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2019 Nov 02; (); Array. doi: 10.1093/cid/ciz1084. Epub 2019 11 02
antitubercular agents delamanid extensively drug-resistant tuberculosis multidrug-resistant tuberculosis
eng

Abstract

Delamanid should be effective against highly resistant strains of M. tuberculosis, but uptake has been slow globally. In the endTB Observational Study, which enrolled one of the largest, most heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% experienced sputum culture conversion within six months.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.